Viragen Inc (fka VRAI)

[heyjoe727]

Should start to see some movement soon

[Celtictrader]

I'm out for now!!!What's the deal between VRA and VGNI???

[backaway]

Resistance today in the mid 0.50's is a bit unexpected! My "boo hooing" is somewhat tempered at present. We shall see.

[backaway]

I be "dazed and confused". Fri. a great PR and PPS rally providing a glimmer of hope. Then, come Mon. the company rushes out a new PR pre market cutting off the rally at the knees. My neck hurts from shaking my head.

[ScovilleUnits]

Holding during premarket with around 700,000 trading.

http://quotes.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?page=afterhours&mkttype=PRE&...

http://www.knobias.com/individual/public/news.htm?eid=3.1.73cc7fb48fd163abb7166681baf0375ff489728b14...


GLTA

[backaway]

OT: I hear you on the WGFL. I'm PATIENTLY in @ 0.0024 and waiting to "tune in" come January. We shall speculate and wait.

[ScovilleUnits]

Well said.

2005 activity and the prior R/S (6-15-04) made Friday's news and pps gain all the more welcome. Here's hoping the test results and product prove successful and that VRA helps many...both the ailing and the shareholders. Hope you get your .90 backaway and use it to go "golfing" around the "World" in that "League" :o). Well, maybe not? LOL.

GLTA.

23-Jun-04 1.50 1.54 1.35 1.40 992,900 1.40
22-Jun-04 1.60 1.65 1.37 1.50 800,500 1.50
21-Jun-04 1.74 1.78 1.53 1.57 672,400 1.57
18-Jun-04 1.78 2.00 1.70 1.70 2,292,900 1.70
17-Jun-04 1.45 1.87 1.43 1.78 2,963,400 1.78
16-Jun-04 1.23 1.45 1.20 1.45 2,007,400 1.45
15-Jun-04 1.22 1.40 1.10 1.25 3,997,500 1.25
15-Jun-04 1 : 10 Stock Split
14-Jun-04 0.16 0.17 0.14 0.14 908,700 1.40
10-Jun-04 0.16 0.17 0.16 0.17 691,800 1.70
9-Jun-04 0.16 0.17 0.16 0.16 134,500 1.60
8-Jun-04 0.17 0.17 0.16 0.16 271,600 1.60
7-Jun-04 0.17 0.17 0.15 0.16 1,357,400 1.60
4-Jun-04 0.15 0.16 0.15 0.16 212,400 1.60
3-Jun-04 0.14 0.15 0.14 0.15 310,200 1.50

[backaway]

Fridays news was a pleasant surprize to say the least considering the past years dive. Sadly, I've got to hit 0.90 to break even. At least, it's FINALLY a glimmer of hope. GLTA

[ScovilleUnits]

Was trading actually halted by VRA or ?


Looks like it was for around 1.5 hours from 1:25 to just short of 3:00? With the volume size reflected looks like the buys were building up for 1.5 hours and then Kaboom!! Looks like the poor folks entering market orders at 1:26ish based on the prior .38 got screwed. Sat on all those open market bids until the price jacked up then-then-then Gotcha!

Intraday Prices (90 second window)
Date Time High Low Close Volume

11/18/05 20:04:03 0.780 0.770 0.780 2,100
11/18/05 19:50:34 0.780 0.780 0.780 14,900
11/18/05 19:04:05 0.790 0.790 0.790 2,900
11/18/05 18:55:05 0.790 0.790 0.790 500
11/18/05 18:50:35 0.800 0.800 0.800 1,000
11/18/05 18:49:05 0.790 0.790 0.790 500
11/18/05 18:44:35 0.800 0.800 0.800 4,900
11/18/05 18:35:35 0.800 0.800 0.800 800
11/18/05 18:34:05 0.810 0.800 0.800 10,300
11/18/05 18:32:35 0.800 0.800 0.800 1,500
11/18/05 18:31:05 0.800 0.800 0.800 21,500
11/18/05 18:29:35 0.800 0.800 0.800 1,000
11/18/05 18:26:36 0.800 0.800 0.800 3,000
11/18/05 18:23:36 0.800 0.800 0.800 4,300
11/18/05 18:22:06 0.800 0.790 0.790 4,200
11/18/05 18:19:06 0.790 0.790 0.790 12,300
11/18/05 18:17:36 0.780 0.780 0.780 15,000
11/18/05 18:16:06 0.790 0.790 0.790 1,000
11/18/05 18:14:36 0.790 0.790 0.790 39,500
11/18/05 18:13:06 0.800 0.800 0.800 35,000
11/18/05 18:11:36 0.800 0.800 0.800 4,900
11/18/05 18:10:06 0.800 0.800 0.800 2,300
11/18/05 18:08:36 0.800 0.800 0.800 600
11/18/05 18:07:06 0.800 0.790 0.790 2,600
11/18/05 18:05:36 0.800 0.780 0.800 6,500
11/18/05 18:04:06 0.800 0.800 0.800 2,500
11/18/05 18:02:36 0.790 0.780 0.780 22,600
11/18/05 18:01:06 0.790 0.780 0.790 5,900
11/18/05 17:59:36 0.790 0.790 0.790 800
11/18/05 17:58:06 0.790 0.790 0.790 100
11/18/05 17:56:36 0.790 0.790 0.790 3,500
11/18/05 17:55:06 0.790 0.790 0.790 14,900
11/18/05 17:53:36 0.790 0.780 0.780 8,000
11/18/05 17:52:06 0.780 0.780 0.780 8,600
11/18/05 17:50:36 0.780 0.770 0.770 3,800
11/18/05 17:49:06 0.770 0.770 0.770 3,900
11/18/05 17:47:36 0.780 0.770 0.780 3,000
11/18/05 17:46:06 0.780 0.780 0.780 2,700
11/18/05 17:44:36 0.780 0.770 0.770 5,000
11/18/05 17:43:06 0.770 0.770 0.770 1,900
11/18/05 17:41:36 0.780 0.780 0.780 500
11/18/05 17:40:07 0.790 0.770 0.790 8,700
11/18/05 17:38:37 0.780 0.780 0.780 3,300
11/18/05 17:37:07 0.780 0.770 0.770 5,400
11/18/05 17:35:37 0.780 0.780 0.780 1,000
11/18/05 17:32:37 0.780 0.780 0.780 2,400
11/18/05 17:31:07 0.780 0.780 0.780 16,100
11/18/05 17:29:37 0.790 0.780 0.790 34,100
11/18/05 17:28:07 0.800 0.800 0.800 1,300
11/18/05 17:26:37 0.810 0.790 0.798 107,000
11/18/05 17:23:37 0.790 0.790 0.790 200
11/18/05 17:22:07 0.790 0.790 0.790 8,500
11/18/05 17:20:37 0.790 0.790 0.790 1,300
11/18/05 17:17:37 0.800 0.780 0.800 12,400
11/18/05 17:16:07 0.800 0.800 0.800 1,000
11/18/05 17:14:37 0.800 0.790 0.790 19,400
11/18/05 17:13:07 0.790 0.790 0.790 1,900
11/18/05 17:11:37 0.790 0.780 0.780 9,100
11/18/05 17:10:07 0.780 0.780 0.780 1,000
11/18/05 17:08:37 0.790 0.780 0.790 13,500
11/18/05 17:07:07 0.800 0.780 0.800 26,800
11/18/05 17:05:37 0.800 0.790 0.790 20,000
11/18/05 17:04:07 0.800 0.780 0.780 5,100
11/18/05 17:02:37 0.800 0.790 0.790 30,800
11/18/05 17:01:07 0.800 0.790 0.800 6,400
11/18/05 16:59:37 0.800 0.790 0.800 10,000
11/18/05 16:58:07 0.800 0.790 0.790 38,200
11/18/05 16:56:37 0.780 0.770 0.780 8,500
11/18/05 16:55:07 0.770 0.770 0.770 8,300
11/18/05 16:53:38 0.800 0.770 0.800 50,600
11/18/05 16:52:08 0.810 0.790 0.800 82,200
11/18/05 16:50:38 0.800 0.790 0.800 18,300
11/18/05 16:49:08 0.790 0.780 0.780 22,700
11/18/05 16:47:38 0.800 0.650 0.650 17,200
11/18/05 16:46:08 0.800 0.800 0.800 11,400
11/18/05 16:44:38 0.810 0.790 0.810 8,400
11/18/05 16:43:08 0.820 0.800 0.820 50,800
11/18/05 16:41:38 0.830 0.800 0.830 40,400
11/18/05 16:40:08 0.830 0.820 0.830 57,500
11/18/05 16:38:38 0.850 0.820 0.830 135,200
11/18/05 16:37:08 0.830 0.770 0.770 118,600
11/18/05 16:35:38 0.820 0.750 0.808 69,300
11/18/05 16:34:08 0.820 0.800 0.820 79,100
11/18/05 16:32:38 0.820 0.800 0.810 56,800
11/18/05 16:31:08 0.860 0.810 0.830 103,100
11/18/05 16:29:38 0.800 0.780 0.790 112,300
11/18/05 16:28:08 0.790 0.760 0.790 86,400
11/18/05 16:26:38 0.780 0.720 0.740 84,700
11/18/05 16:25:08 0.790 0.720 0.720 104,200
11/18/05 16:23:38 0.720 0.680 0.690 55,700
11/18/05 16:22:08 0.700 0.640 0.640 18,100
11/18/05 16:20:38 0.640 0.640 0.640 13,000
11/18/05 16:19:08 0.640 0.630 0.630 6,000
11/18/05 16:16:08 0.610 0.610 0.610 5,000
11/18/05 16:13:08 0.610 0.610 0.610 9,900
11/18/05 16:11:38 0.610 0.610 0.610 11,100
11/18/05 16:10:08 0.640 0.640 0.640 3,000
11/18/05 16:08:38 0.650 0.640 0.650 1,100
11/18/05 16:05:39 0.670 0.650 0.660 54,000
11/18/05 16:04:09 0.670 0.640 0.660 106,300
11/18/05 16:02:39 0.660 0.640 0.660 265,700
11/18/05 16:01:09 0.660 0.650 0.660 114,500
11/18/05 15:59:39 0.660 0.640 0.650 146,100
11/18/05 15:58:09 0.660 0.640 0.660 81,600
11/18/05 15:56:39 0.670 0.650 0.660 118,300
11/18/05 15:55:09 0.690 0.670 0.680 343,600
11/18/05 15:53:39 0.690 0.670 0.670 194,400
11/18/05 15:52:09 0.680 0.660 0.680 97,100
11/18/05 15:50:39 0.670 0.650 0.660 85,200
11/18/05 15:49:09 0.680 0.650 0.660 122,800
11/18/05 15:47:39 0.680 0.660 0.660 107,800
11/18/05 15:46:09 0.680 0.660 0.660 97,500
11/18/05 15:44:39 0.660 0.650 0.650 264,800
11/18/05 15:43:09 0.650 0.640 0.640 154,500
11/18/05 15:41:39 0.650 0.640 0.650 108,800
11/18/05 15:40:09 0.680 0.550 0.680 140,200
11/18/05 15:38:39 0.630 0.610 0.620 70,200
11/18/05 15:37:09 0.620 0.600 0.620 94,200
11/18/05 15:35:39 0.620 0.610 0.620 91,400
11/18/05 15:34:09 0.620 0.610 0.610 104,000
11/18/05 15:32:39 0.630 0.610 0.630 80,400
11/18/05 15:31:09 0.670 0.630 0.670 112,300
11/18/05 15:29:39 0.670 0.650 0.670 212,300
11/18/05 15:28:09 0.670 0.640 0.640 160,700
11/18/05 15:26:39 0.640 0.620 0.620 98,400
11/18/05 15:25:09 0.640 0.620 0.630 101,000
11/18/05 15:23:39 0.640 0.630 0.640 90,000
11/18/05 15:22:09 0.640 0.630 0.640 48,500
11/18/05 15:20:40 0.640 0.500 0.620 86,700
11/18/05 15:19:10 0.660 0.631 0.649 207,500
11/18/05 15:17:40 0.680 0.650 0.660 158,300
11/18/05 15:16:10 0.680 0.640 0.640 378,100
11/18/05 15:14:40 0.650 0.620 0.630 257,600
11/18/05 15:13:10 0.630 0.610 0.630 177,300
11/18/05 15:11:40 0.640 0.610 0.620 220,900
11/18/05 15:10:10 0.620 0.590 0.590 182,200
11/18/05 15:08:40 0.590 0.570 0.570 105,500
11/18/05 15:07:10 0.580 0.550 0.580 141,100
11/18/05 15:05:40 0.580 0.550 0.550 208,200
11/18/05 15:04:10 0.560 0.540 0.550 131,600
11/18/05 15:02:40 0.600 0.520 0.530 245,500
11/18/05 15:01:10 0.620 0.389 0.600 148,700
11/18/05 14:59:40 0.650 0.580 0.600 421,200
11/18/05 14:58:10 0.590 0.420 0.420 679,700
11/18/05 13:25:12 0.380 0.380 0.380 14,900
11/18/05 13:19:12 0.380 0.380 0.380 6,100
11/18/05 13:16:12 0.380 0.380 0.380 10,000
11/18/05 13:04:12 0.380 0.380 0.380 400
11/18/05 13:02:42 0.380 0.380 0.380 100
11/18/05 12:53:43 0.380 0.380 0.380 100
11/18/05 12:52:13 0.380 0.380 0.380 10,100
11/18/05 12:46:13 0.380 0.380 0.380 7,000
11/18/05 12:37:13 0.380 0.380 0.380 100
11/18/05 12:23:43 0.390 0.389 0.389 500
11/18/05 12:16:13 0.380 0.380 0.380 100
11/18/05 12:14:43 0.389 0.389 0.389 100
11/18/05 12:10:14 0.380 0.380 0.380 1,000
11/18/05 12:01:14 0.390 0.380 0.380 13,000
11/18/05 11:53:44 0.380 0.380 0.380 100
11/18/05 11:35:44 0.380 0.380 0.380 100
11/18/05 11:29:44 0.390 0.390 0.390 5,000
11/18/05 11:26:45 0.390 0.390 0.390 5,000
11/18/05 11:25:15 0.380 0.380 0.380 10,200
11/18/05 11:20:45 0.380 0.380 0.380 9,500
11/18/05 11:13:15 0.380 0.380 0.380 49,900
11/18/05 11:11:45 0.380 0.380 0.380 800
11/18/05 11:10:15 0.380 0.370 0.370 18,500
11/18/05 11:08:45 0.370 0.360 0.360 4,100
11/18/05 11:07:15 0.370 0.370 0.370 300
11/18/05 10:44:45 0.370 0.370 0.370 2,700
11/18/05 10:43:15 0.370 0.370 0.370 800
11/18/05 10:26:46 0.360 0.360 0.360 200
11/18/05 10:14:46 0.380 0.370 0.380 1,100
11/18/05 10:13:16 0.380 0.380 0.380 500
11/18/05 10:08:46 0.379 0.379 0.379 500
11/18/05 10:07:16 0.370 0.370 0.370 5,000
11/18/05 09:59:46 0.370 0.370 0.370 5,000
11/18/05 09:58:16 0.370 0.370 0.370 5,000
11/18/05 09:55:16 0.360 0.360 0.360 100
11/18/05 09:52:17 0.360 0.360 0.360 2,000
11/18/05 09:50:47 0.360 0.360 0.360 3,100

[Celtictrader]

Nice news today after the halt!!!I wish I would have bought more..

[yielddude]

The solution to costly drugs: Chickens
Viragen's biochickens lay eggs laced with anti-cancer drugs cheaper than using bioreactors.
October 26, 2005: 5:27 PM EDT
By Aaron Smith, CNN/Money staff writer

NEW YORK (CNN/Money) - Manufacturing drugs in factories is expensive. So why not have chickens do it instead?

Viragen (up $0.01 to $0.45, Research), a Florida-based biotech, is developing a method to produce drugs inside chickens, rather than expensive bioreactors. At Viragen, the chickens have become the bioreactors, and the factories have turned into "Hilton" quality chicken farms, said Dr. Helen Sang, project leader.

"Our aim is to make drugs in hens' eggs, but the drugs will all be protein drugs," said Sang, a senior scientist with the Roslin Institute, the Scottish research center that brought us Dolly the cloned sheep. "What we are looking for is a new way to produce the protein that would be cheaper and, more importantly, produce high-quality products."

Vaccine makers have been culturing drugs inside eggs for at least 30 years. But unlike the vaccine makers, Viragen's scientists don't wait for the hen to lay the egg. Using a process called avian transgenics, Viragen's scientists bioengineer the chickens with an artificial gene, which directs the hens to lay eggs with protein-based drugs inside the protein-rich whites, said CEO Charles Rice. Then, the scientists extract the protein antibodies from the eggs. There are various ways to extract the proteins, including centrifuge, or spinning the eggs until the protein is forced to the surface of the white. Meanwhile, the chickens pass on the drug gene to their offspring.

Viragen's flock of hens has already laid eggs laced with a protein antibody that fights skin cancer. Rice said this method, conducted with the Memorial Sloan-Kettering Cancer Center of New York, is still in preclinical trials.

Next, Viragen hopes to produce eggs containing insulin, the protein that occurs naturally in healthy people but must be artificially injected by diabetics to help control blood-sugar levels. Rice wouldn't project sales, but the potential is huge, considering the American Diabetes Association's estimate of 18.2 million Americans with diabetes, with another 1.3 million diagnosed annually.

Viragen would contract its biochickens to drug makers who need help producing protein-based drugs. Rice said that Viragen might be able to help Genentech (up $1.15 to $89.52, Research), a California biotech, produce Herceptin, a gene-targeted treatment for breast cancer, and Rituxan, a treatment for non-Hodgkin's lymphoma.

"If Genentech runs short of production facilities for Herceptin, we can breed a few hundred more chickens at our chicken farm," said Rice.

Viragen's chickens each lay about 250 eggs per year. The company is experimenting with producing multiple doses inside a single egg, said Sang, but she added, "We don't want to be greedy."

Rice said Viragen would receive 20 to 50 percent of a drug's sales when it contracts production for another company, focusing on blockbusters, or drugs with blockbuster potential. This explains Rice's interest in Genentech: Herceptin sales totaled nearly $500 million for Genentech in the first nine months of 2005, about a 40 percent jump from the same period last year, while Rituxan sales totaled $1.3 billion in the first nine months.

"There's no product that I could envision working on with less than $1 billion market value," said Rice.

Eric Schmidt, analyst for SG Cowen, said that Genentech's capacity is maxed out, so they might be amenable to new methods of drug production.

"The potential opportunity for Viragen is that Genentech is running at 100 percent [capacity]," said Schmidt. "Their capacity is bursting at the seams. They might be receptive to new technology that would increase their input and decrease their cost."

However, large drug companies like Genentech are sometimes reluctant to switch their manufacturing methods because it could create complications with regulatory agencies, said Jason Kantor, analyst for RBC Capital Markets.

"There are a lot of alternative manufacturing technologies that are in development, including yeast, plant cells, whole plants, transgenic animals and, in this case, chicken eggs," said Kantor. "The big limitation here is that big companies are reluctant, from a quality control and regulatory standpoint, to change their manufacturing process. There is significant regulatory risk in trying to change manufacturing technology."

In addition to its work with avian transgenics, Viragen produces Multiferon, a treatment for viruses and cancers that is marketed in 10 countries outside the U.S. The company reported $278 million in sales during the 12 months ended June 30, 2005, with a net loss of $26 million.

[backaway]

Jonathan Lebed seems interested in VRA! We shall see.

[jmac]

Director and CEO have bought shares this year at higher prices than it is now:

23-Aug-05 STAFFORD, C. RICHARD
Director 50,000 Direct Private Purchase at $0.62 per share. $31,000
9-May-05 STAFFORD, C. RICHARD
Director 25,000 Direct Purchase at $0.62 per share. $15,500
5-Apr-05 STAFFORD, C. RICHARD
Director 21,931 Direct Purchase at $0.66 per share. $14,474
21-Jan-05 RICE, CHARLES A.
Chief Executive Officer 60,000 Direct Purchase at $0.90 per share. $54,000
20-Jan-05 RICE, CHARLES A.
Chief Executive Officer 20,000 Direct Purchase at $0.88 per share. $17,600
13-Dec-04 SINGER, CARL N.
Director 36,000 Direct Purchase at $0.95 per share. $34,200

[jmac]

from co
"We believe Viragen's Multiferon (natural human alpha
interferon), represents a prime candidate worthy of evaluation for
virtually any emerging viral threat, and we have previously filed
patents associated with Multiferon for the possible treatment of avian
flu. We have also previously disclosed that certain government studies
are ongoing that are evaluating Multiferon for a range of viral threats,
but we are prevented from sharing any information regarding these
studies at this time."

[backaway]

Been a LONG dry spell for VRA but the Multiferon phase III passed so this week we'll see some movement. GLTA

[Versatiletrader]

Alert went off for VRA.
I'm watching.
current price is .96- 1.04 range
Keep it on your radar.

[knight74]

Has anyone checked out the 50day, 200 day moving averages.
Also have you noticed the hugh volume?
Accumulation.....

I'm watching this one.
Checkout the charts, I see something is cooking.
knight

[fisk5o]

Lets hope we start heading in the right direction.Good luck All.

[glassguy]

The new brought up to close at .29 today, looks maybe a breakout again, pretty good vol. lets keep it up.

[simpsonrc1]

EquityOutlook.Com Announces Stock Evaluation Ratings for Intel, Viragen Inc., Amgen, JP Morgan, NVIDIA
28 Jul 2003, 10:22am ET
E-mail or Print this story
- - - - -

SHREVEPORT, La.--(BUSINESS WIRE)--July 28, 2003--EquityOutlook.Com makes these short-term stock recommendations:

Intel (NASDAQ:INTC) - SELL
Viragen Inc (AMEX:VRA) - BUY
Amgen (NASDAQ:AMGN) - SELL
JP Morgan (NYSE:JPM) - SELL
NVIDIA (NASDAQ:NVDA) - STRONG BUY

WHAT THESE RATINGS MEAN:

EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a "long term" view of any company listed. These are ratings that reflect our opinion of a stock's potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to -10 (which indicates our belief that a stock has a great chance to move lower). These ratings may change based on daily market conditions.

ABOUT EquityOutlook.Com:

EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

EquityOutlook.Com's goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com .

CONTACT: EquityOutlook.Com
Chester T. Kelley, 318/212-0640

SOURCE: EquityOutlook.Com

[simpsonrc1]

glass- here's something should apply to vra:

http://www.investorshub.com/boards/read_msg.asp?message_id=1247658

Check (chart) out what SARS did for aegn this past may.

http://finance.lycos.com/home/stocks/charts.asp?symbols=NASDAQ:AEGN

In case you don't want to log on (it's free) here is the abstract:

Home The Journal Current Issue Original research
Volume 362, Number 9380 26 July 2003
Research letters
Treatment of SARS with human interferons
J Cinatl, B Morgenstern, G Bauer, P Chandra, H Rabenau, H W Doerr
Effective antiviral agents are needed to treat severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection. We assessed the antiviral potential of recombinant interferons against two clinical isolates of SARS-CoV--FFM-1, from Frankfurt patients, and Hong Kong--replicated in Vero and Caco2 cells. Interferon ß was five to ten times more effective in Caco2 cells. Interferon effectively inhibited SARS-CoV replication, but with a selectivity index 50-90 times lower than that for interferon ß. Interferon was slightly better than interferon in Vero cell cultures, but was completely ineffective in Caco2 cell cultures. Interferon ß could be useful alone or in combination with other antiviral drugs for the treatment of SARS.

Lancet 2003; 362: 293-94

[glassguy]

this stock is a very roller coaster stock, ups and downs but overall very healthy company with some good promise of upward trend again.

[simpsonrc1]

vra being watched:

http://ragingbull.lycos.com/mboard/boards.cgi?board=EMLX&read=35722


http://ragingbull.lycos.com/mboard/boards.cgi?board=EMLX&read=35724

[simpsonrc1]

in today @ .25. let's get this board going.

[glassguy]

came from raggin bull, anyone here have this seems to be a very good stock if they can move.